What is Immuron?
Founded in 1994, Immuron operates at the intersection of immunology and pharmaceutical innovation. The company specializes in the research, development, and commercialization of targeted polyclonal antibodies designed to address inflammatory-mediated and infectious diseases. By leveraging an oral delivery mechanism, Immuron distinguishes itself from traditional injectable biologics, offering a unique value proposition in the global healthcare market. Its clinical-stage status reflects a mature operational framework, positioning the firm as a key player in the Australian biotechnology sector with significant potential for international scalability.
How much funding has Immuron raised?
Immuron has raised a total of $26.1M across 2 funding rounds:
Stock Offering
$6.1M
Other Financing Round
$20M
Stock Issuance/Offering (2017): $6.1M, investors not publicly disclosed
Other Financing Round (2020): $20M, investors not publicly disclosed
Key Investors in Immuron
Undisclosed Institutional Investor
A private investment entity focused on supporting clinical-stage biopharmaceutical companies with long-term growth potential.
Undisclosed Strategic Partner
A specialized venture firm providing capital and operational expertise to firms developing novel therapeutic modalities.
Undisclosed Equity Firm
An investment group specializing in public market equity offerings for high-growth healthcare and life sciences organizations.
What's next for Immuron?
With the recent injection of $20M, Immuron is strategically positioned to scale its clinical trial operations and expand its research initiatives. The company is expected to prioritize the advancement of its lead assets, focusing on data readout milestones and potential regulatory submissions. By optimizing its manufacturing processes and strengthening its intellectual property portfolio, Immuron aims to solidify its market position. Future growth will likely be driven by strategic partnerships and the continued validation of its oral antibody platform, which remains a cornerstone of its long-term commercialization strategy.
See full Immuron company page
